Liewei Wang: Inhibition of MTAP Increases PARP Inhibitor Susceptibility in Triple-Negative Breast Cancer
Liewei Wang, Professor and Chair of Pharmacology at Mayo Clinic Graduate School of Biomedical Sciences, shared a recent article she and her colleagues co-authored on LinkedIn , adding:
“Another great collaboration with Dr. Zhenkun Lou’s lab!
We recently published in JCI showing that in TNBC, inhibition of MTAP leads to lower SAM level, blunts the methylation of DNA repair proteins including MRE11, therefore, reducing HRR efficiency.
MTAP inhibition can sensitize PARP inhibitors, leading to striking tumor growth inhibition, especially in the setting of brain metastasis where methine is limited.”
Title: Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop
Authors: Xiangyu Zeng, Fei Zhao, Xinyi Tu, Yong Zhang, Wen Yang, Jing Hou, Qi Jiang, Shouhai Zhu, Zheming Wu, Yalan Hao, Lingxin Zhang, Richard M. Weinshilboum, Kaixiong Tao, Liewei Wang, Zhenkun Lou
Read the Full Article on JCI
More posts featuring Triple-Negative Breast Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023